XRTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

XRTX ▲ +56.73% at T+20d

NEUTRAL call ✓ call won +56.73% · α vs SPY +43.99% · entry $1.90 → $2.97

Next anchor: T+60d in 13d

Currently $2.30 · +21.37% from $1.90 entry

Entry anchored
Mar 26, 02:05 PM ET
via Databento tick

T+1d

+1.06%

call +1.06% · α +1.41%

$1.92

settled 3mo ago

T+5d

+22.43%

call +22.43% · α +18.57%

$2.32

settled 2mo ago

T+20d

+56.73%

call +56.73% · α +43.99%

$2.97

settled 7w ago

T+60d

—

call — · α —

—

in 13d

Price Chart

Loading chart...

Executive Summary

XORTX Therapeutics has delayed its planned 1-for-5 share consolidation from March 27, 2026, to April 6, 2026, pending final approvals from the TSX Venture Exchange and Nasdaq. The delay introduces uncertainty around the timing of capital structure changes for this micro-cap pharmaceutical company with multiple late-stage kidney disease programs in development.

Actionable Insight

Traders should monitor for exchange approvals and the final implementation of the share consolidation, which could affect liquidity and stock volatility. The small market cap makes XRTX susceptible to speculative moves around structural changes.

Key Facts

XORTX delayed its 1-for-5 share consolidation from March 27, 2026, to April 6, 2026.
The share consolidation remains subject to approval by the TSX Venture Exchange and Nasdaq.
The company is developing three clinical-stage therapies: XRx-026 (gout), XRx-008 (ADPKD), and XRx-101 (acute kidney injury).
XRTX has a market cap of $3M and trades on Nasdaq, TSXV, and Frankfurt exchanges.

Financial Impact

No immediate financial impact; potential reduction in share count by 80% upon completion of consolidation.

share countstock priceliquidity

Risk Factors

Risk that TSXV or Nasdaq may not approve the consolidation, leading to further delays or cancellation.
Low market cap and thin trading volume could amplify volatility post-consolidation.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3263445

12 reports for XRTX

T+1T+5T+20T+60

50% Hit rate 3 of 6 directional calls best @ T+5▲ +23.96%Apr 13, 2026

Filters

Reports for XRTX — sortable, filterable
	Type				Now
May 19, 2026 21d ago	6-K / PRESS-RELEASE BEARISH ★ 6/10	$2.32 $2.40	▼ −3.45%	▼ −1.15%	$2.30 (+0.86%)
May 15, 2026 25d ago	424B4 BEARISH ★ 7/10	$2.59 $2.18	▲ +15.83%	▲ +16.79%	$2.30 (+11.20%)
May 14, 2026 26d ago	6-K BEARISH ★ 7/10	$2.01 $2.31	▼ −14.93%	▼ −15.64%	$2.30 (−14.43%)
May 14, 2026 26d ago	Press Release BEARISH ★ 6/10	$2.01 $2.31	▼ −14.93%	▼ −15.64%	$2.30 (−14.43%)
Apr 21, 2026 7w ago	6-K NEUTRAL ★ 5/10	$2.69 $2.77	▲ +2.97%	▲ +1.89%	$2.30 (−14.50%)
Apr 16, 2026 7w ago	6-K BULLISH ★ 7/10	$2.44 $2.77	▲ +13.52%	▲ +12.54%	$2.30 (−5.74%)
Apr 13, 2026 8w ago	Press Release BULLISH ★ 7/10	$2.17 $2.69	▲ +23.96%	▲ +22.57%	$2.30 (+5.99%)
Mar 27, 2026 10w ago	6-K NEUTRAL ★ 3/10	$1.90 $2.32	▲ +22.43%	▲ +18.57%	$2.30 (+21.37%)
Mar 27, 2026 10w ago	6-K NEUTRAL ★ 3/10	$1.90 $2.32	▲ +22.43%	▲ +18.57%	$2.30 (+21.37%)
Mar 26, 2026 10w ago	Press Release NEUTRAL ★ 4/10	$1.90 $2.32	▲ +22.43%	▲ +18.57%	$2.30 (+21.37%)

US Market Status

Market Closed — Opens Thu (10h 56m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access